Thymulin vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymulin
Thymulin (Facteur Thymique Sérique) is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. It plays important roles in T-cell differentiation and immune system maturation.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | Thymulin | Teriparatide |
|---|---|---|
| Mechanism | Requires zinc for biological activity. Promotes T-cell differentiation, modulates cytokine production, and influences neuroendocrine function. Levels decline significantly with age. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Research protocols vary. Often studied alongside zinc supplementation. Typical research doses in the microgram range. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous or intramuscular injection in research settings. Requires adequate zinc status for activity. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Limited data on exogenous administration. Theoretical effects on immune function require monitoring. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |